Lindbrook Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | $161K | Buy |
596
+50
| +9% | +$13.5K | 0.01% | 484 |
|
|
2024
Q4 | $128K | Sell |
546
-24
| -4% | -$5.65K | 0.01% | 486 |
|
|
2024
Q3 | $157K | Buy |
570
+57
| +11% | +$15.7K | 0.01% | 443 |
|
|
2024
Q2 | $125K | Buy |
513
+277
| +117% | +$67.3K | 0.01% | 469 |
|
|
2024
Q1 | $35.3K | Sell |
236
-133
| -36% | -$19.9K | ﹤0.01% | 927 |
|
|
2023
Q4 | $70.6K | Buy |
369
+100
| +37% | +$19.1K | 0.01% | 635 |
|
|
2023
Q3 | $47.6K | Buy |
269
+22
| +9% | +$3.9K | 0.01% | 712 |
|
|
2023
Q2 | $46.9K | Buy |
247
+45
| +22% | +$8.55K | 0.01% | 741 |
|
|
2023
Q1 | $40.5K | Sell |
202
-54
| -21% | -$10.8K | ﹤0.01% | 772 |
|
|
2022
Q4 | $60.8K | Buy |
256
+41
| +19% | +$9.74K | 0.01% | 621 |
|
|
2022
Q3 | $43K | Buy |
215
+46
| +27% | +$9.2K | 0.01% | 698 |
|
|
2022
Q2 | $25K | Buy |
169
+3
| +2% | +$444 | ﹤0.01% | 885 |
|
|
2022
Q1 | $27K | Sell |
166
-17
| -9% | -$2.77K | ﹤0.01% | 880 |
|
|
2021
Q4 | $31K | Sell |
183
-3
| -2% | -$508 | ﹤0.01% | 876 |
|
|
2021
Q3 | $35K | Buy |
186
+13
| +8% | +$2.45K | 0.01% | 544 |
|
|
2021
Q2 | $29K | Sell |
173
-8
| -4% | -$1.34K | 0.01% | 643 |
|
|
2021
Q1 | $26K | Buy |
181
+15
| +9% | +$2.16K | 0.01% | 647 |
|
|
2020
Q4 | $22K | Buy |
166
+5
| +3% | +$663 | 0.01% | 640 |
|
|
2020
Q3 | $23K | Buy |
161
+102
| +173% | +$14.6K | 0.01% | 561 |
|
|
2020
Q2 | $9K | Buy |
59
+7
| +13% | +$1.07K | ﹤0.01% | 854 |
|
|
2020
Q1 | $6K | Buy |
+52
| New | +$6K | ﹤0.01% | 905 |
|